Cargando…
Neoantigens and their potential applications in tumor immunotherapy
The incidence of malignant tumors is increasing, the majority of which are associated with high morbidity and mortality rates worldwide. The traditional treatment method for malignant tumors is surgery, coupled with radiotherapy or chemotherapy. However, these therapeutic strategies are frequently a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805178/ https://www.ncbi.nlm.nih.gov/pubmed/35126730 http://dx.doi.org/10.3892/ol.2022.13208 |
_version_ | 1784643190289072128 |
---|---|
author | Fang, Xianzhu Guo, Zhiliang Liang, Jinqing Wen, Jiao Liu, Yuanyuan Guan, Xiumei Li, Hong |
author_facet | Fang, Xianzhu Guo, Zhiliang Liang, Jinqing Wen, Jiao Liu, Yuanyuan Guan, Xiumei Li, Hong |
author_sort | Fang, Xianzhu |
collection | PubMed |
description | The incidence of malignant tumors is increasing, the majority of which are associated with high morbidity and mortality rates worldwide. The traditional treatment method for malignant tumors is surgery, coupled with radiotherapy or chemotherapy. However, these therapeutic strategies are frequently accompanied with adverse side effects. Over recent decades, tumor immunotherapy shown promise in demonstrating notable efficacy for the treatment of cancer. With the development of sequencing technology and bioinformatics algorithms, neoantigens have become compelling targets for cancer immunotherapy due to high levels of immunogenicity. In addition, neoantigen-based vaccines have demonstrated potential for cancer therapy, primarily by augmenting T-cell responses. Neoantigens have also been shown to be effective in immune checkpoint blockade therapy. Therefore, neoantigens may serve to be predictive biomarkers and synergistic treatment targets in cancer immunotherapy. The aim of the present review was to provide an overview of the recent progress in the classification, screening and clinical application of neoantigens for cancer therapy. |
format | Online Article Text |
id | pubmed-8805178 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-88051782022-02-03 Neoantigens and their potential applications in tumor immunotherapy Fang, Xianzhu Guo, Zhiliang Liang, Jinqing Wen, Jiao Liu, Yuanyuan Guan, Xiumei Li, Hong Oncol Lett Review The incidence of malignant tumors is increasing, the majority of which are associated with high morbidity and mortality rates worldwide. The traditional treatment method for malignant tumors is surgery, coupled with radiotherapy or chemotherapy. However, these therapeutic strategies are frequently accompanied with adverse side effects. Over recent decades, tumor immunotherapy shown promise in demonstrating notable efficacy for the treatment of cancer. With the development of sequencing technology and bioinformatics algorithms, neoantigens have become compelling targets for cancer immunotherapy due to high levels of immunogenicity. In addition, neoantigen-based vaccines have demonstrated potential for cancer therapy, primarily by augmenting T-cell responses. Neoantigens have also been shown to be effective in immune checkpoint blockade therapy. Therefore, neoantigens may serve to be predictive biomarkers and synergistic treatment targets in cancer immunotherapy. The aim of the present review was to provide an overview of the recent progress in the classification, screening and clinical application of neoantigens for cancer therapy. D.A. Spandidos 2022-03 2022-01-21 /pmc/articles/PMC8805178/ /pubmed/35126730 http://dx.doi.org/10.3892/ol.2022.13208 Text en Copyright: © Fang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Review Fang, Xianzhu Guo, Zhiliang Liang, Jinqing Wen, Jiao Liu, Yuanyuan Guan, Xiumei Li, Hong Neoantigens and their potential applications in tumor immunotherapy |
title | Neoantigens and their potential applications in tumor immunotherapy |
title_full | Neoantigens and their potential applications in tumor immunotherapy |
title_fullStr | Neoantigens and their potential applications in tumor immunotherapy |
title_full_unstemmed | Neoantigens and their potential applications in tumor immunotherapy |
title_short | Neoantigens and their potential applications in tumor immunotherapy |
title_sort | neoantigens and their potential applications in tumor immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805178/ https://www.ncbi.nlm.nih.gov/pubmed/35126730 http://dx.doi.org/10.3892/ol.2022.13208 |
work_keys_str_mv | AT fangxianzhu neoantigensandtheirpotentialapplicationsintumorimmunotherapy AT guozhiliang neoantigensandtheirpotentialapplicationsintumorimmunotherapy AT liangjinqing neoantigensandtheirpotentialapplicationsintumorimmunotherapy AT wenjiao neoantigensandtheirpotentialapplicationsintumorimmunotherapy AT liuyuanyuan neoantigensandtheirpotentialapplicationsintumorimmunotherapy AT guanxiumei neoantigensandtheirpotentialapplicationsintumorimmunotherapy AT lihong neoantigensandtheirpotentialapplicationsintumorimmunotherapy |